Eris Lifesciences Ltd is the only publicly listed Indian pharmaceutical company with a pure-play domestic branded formulations business model. Ranked #21 in the IPM, Eris has established a leading presence in its core cardio-metabolic franchise in just 15 years from inception. Eris is also successfully diversifying its business with 3 emerging therapies (Dermatology, Neuropsychiatry and Gynaecology) accounting for 20% of its revenue and growing at > 25% p.a.

We began our journey 15 years ago in 2007 with the vision to make a meaningful impact in the management of chronic lifestyle related diseases. Today Chronic and Sub-chronic therapies account for ~ 90% of our revenue, and our product range spans ~ 90% of India’s Rs. 55,000+ crore chronic care market. Our business model is pivoted around specialist/ super specialist doctors and high end consulting physicians. We consistently endeavour to channel the advantages of cutting-edge medical knowledge to aid our clinicians and patients with better disease management options and outcomes.

Our market engagement consists of two pillars – (i) Patient Care Initiatives (PCI), and (ii) India-Centric Studies. Through our PCI platform, we bring cutting edge diagnosis and monitoring technologies to patients. The insights from these interventions are immensely useful to our physicians in managing the health outcomes of their patients. Examples of such interventions include Ambulatory Blood Pressure Monitoring (ABPMs), Continuous Glucose Monitoring (CGMs), Holter Devices, Sleep Studies, etc. Our second engagement pillar, India-centric Studies was born out of the imperative to generate and use India-centric data in the diagnosis and management of cardio-metabolic conditions. In FY21 the results of our first such study – The India Heart Study (IHS) – were published in the Journal of Hypertension, which is the official journal of the European Society of Hypertension. On the back of the success of the IHS, we recently concluded the India Diabetes Study (IDS), the results of which were published in April 2022 in the Public Library of Science (PLOS) journal.

Diabetes care is our flagship therapy contributing to 29% of our FY22 branded formulations revenue and in our Oral Diabetes covered market, we rank among the Top-5 companies in India in revenue share as well as prescription share. We have extended our presence to the Insulin franchise at the start of CY22. Cardiac care is our second largest therapy at 24% of our revenue, followed by the VMN category at 16% of revenue. We have 3 emerging therapies – Dermatology, Neuropsychiatry and Gynaecology – collectively accounting for 20% of our branded formulations revenue. Put together, our Top-6 therapies account for ~ 90% of our revenue.

We have a fully integrated business model with our manufacturing facility in Guwahati contributing to ~ 80% of the products sold during FY22. Our upcoming manufacturing facility in Gujarat, which is expected to be operational by end of CY22, will further augment our manufacturing capabilities. We have a pan-India distribution network with 2,000+ stockists and 5,00,000+ chemists. Over 4,200 Erisians work at our offices in Ahmedabad and Mumbai, at our manufacturing facility and on the field across the nation.

We clocked a consolidated operating revenue of INR 13,470 mn in FY22, registering a growth of 5x in the 10 year period since FY12. Our net profits have grown 11x in the last 10 years to INR 4,058 mn in FY22. We have maintained an ROIC in excess of 30% for the last 13 years in a row.

15 years into our existence, the fundamental pillars of our business remain intact – chronic and specialty focused domestic business with a low NLEM exposure, leading brands in core therapies, high margins and return metrics, industry leading cash generation and a strong debt-free balance sheet. We look forward to harness the power of these pillars as we drive the next leg of our growth journey.